Document Detail

Comparison of metabolic and prolactin variables from a six-month randomised trial of olanzapine and quetiapine in schizophrenia.
MedLine Citation:
PMID:  19240085     Owner:  NLM     Status:  MEDLINE    
Schizophrenia patients have a potential increased risk of metabolic dysregulation during antipsychotic treatments. Our objective was to compare changes in prolactin and metabolic variables (glucose, lipids and weight) as a post-hoc analysis from a six-month, randomised, controlled study of olanzapine (OLZ, n = 171; 10-20 mg/day) or quetiapine (QUE, n = 175; 300-700 mg/day). No statistically significant treatment group differences for baseline to endpoint mean changes in body mass index (P = 0.209) or weight (P = 0.250) were observed. There was a greater incidence of clinically significant weight gain (defined as > or =7% increase from baseline) in OLZ (19.2%) compared to QUE (13.2%)-treated patients (P = 0.181). No statistically significant treatment group differences for lipids and glucose variables, either as mean change from baseline to endpoint or treatment-emergent (TE) categorical changes were found (P > or = 0.05). Incidence rates for TE diabetes were similar between treatment groups 2.5% (n = 4) in the OLZ-treatment group and 1.3% (n = 2) in the QUE-treatment group (P = 0.685). Hyperprolactinaemia was present at baseline in many patients (OLZ 32.9%; QUE 31.4%), but after 2 weeks of treatment prolactin values had reverted to normal for nearly all patients (OLZ 100%; QUE 99.4%). There were no significant treatment differences in any variable between cohorts.
C Bushe; J Sniadecki; A J Bradley; V Poole Hoffmann
Related Documents :
12725705 - Addition of rosiglitazone to existing sulfonylurea treatment in chinese patients with t...
10361905 - Secondary prevention with lipid lowering therapy in familial hypercholesterolemia: a co...
6420965 - Long-term treatment of onchocerciasis patients from the liberian rain-forest with low d...
16382385 - Pregnancy-associated spontaneous coronary artery dissection: impact of medical treatmen...
20695925 - An exploratory analysis of factors associated with weight change in a 16-week trial of ...
24255595 - Prostatectomy using different lasers for the treatment of benign prostate hyperplasia i...
Publication Detail:
Type:  Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial     Date:  2009-02-24
Journal Detail:
Title:  Journal of psychopharmacology (Oxford, England)     Volume:  24     ISSN:  1461-7285     ISO Abbreviation:  J. Psychopharmacol. (Oxford)     Publication Date:  2010 Jul 
Date Detail:
Created Date:  2010-06-17     Completed Date:  2010-09-16     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8907828     Medline TA:  J Psychopharmacol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1001-9     Citation Subset:  IM    
Eli Lilly and Company, Basingstoke, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antipsychotic Agents / adverse effects*,  therapeutic use*
Benzodiazepines / adverse effects*,  therapeutic use*
Blood Glucose / metabolism
Body Mass Index
Body Weight
Dibenzothiazepines / adverse effects*,  therapeutic use*
Double-Blind Method
Lipid Metabolism / drug effects,  physiology
Middle Aged
Prolactin / blood*
Psychotic Disorders / blood,  drug therapy,  psychology
Schizophrenia / blood,  drug therapy*,  metabolism*
Schizophrenic Psychology
Weight Gain / drug effects
Reg. No./Substance:
0/Antipsychotic Agents; 0/Blood Glucose; 0/Dibenzothiazepines; 0/quetiapine; 12794-10-4/Benzodiazepines; 132539-06-1/olanzapine; 9002-62-4/Prolactin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Trends in the prevalence and incidence of diabetes in the UK: 1996-2005.
Next Document:  Antidepressants that inhibit neuronal norepinephrine reuptake are not associated with increased spon...